SK3 Group, Inc. (USOTC:SKTO)
Historical Stock Chart
5 Years : From Apr 2012 to Apr 2017
SK3 Group, Inc. (PINKSHEETS: SKTO) ("the Company") has announced that its licensed products are seeing wide distribution across California. As of July 2013, the Company's recipes and brands can be found in over 58 medical cannabis dispensaries throughout California. Some of these products include Yak Whole Plant Extract Capsules in Indica, Sativa and High CBD, which contain the non-psychoactive cannabinoid cannabidiol, Yak Haute Chocolate instant chocolate drink, Yak Mocha-Juana instant chocolate & coffee drink, Yak Greenie Whole Plant Extract Cookie, Yeti Premium Preroll for powerful pain relief which contains high-quality cannabis flowers impregnated with potent Red Diamond oil, and Organakoil whole plant extract which is used for the "Simpson Treatment." The Company is undertaking strategies to ensure that the number of retail points selling these licensed products continues to grow aggressively in the coming months.
A. Mayer, President SK3 Group, said, " Mass distribution in the States that are now selling medical cannabis is the key to the growth of the company and ultimately the revenue and we feel we are making great strides toward that end."
About SK3 Group, Inc.
SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes", "expects", "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. This news release speaks as of the date first set forth above and no responsibility or obligation may be assumed or exists to update the information included herein for events occurring after the date hereof.
Investor Relations Contact
TEL: 855-868-7577 (Dial 1 for direct IR)